Compare Best Buy Co Inc (BBY) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Best Buy Co Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Best Buy Co Inc trades at $83.5 (market cap $17.37B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 4.8× Best Buy Co Inc's market cap, and Best Buy Co Inc pays the higher dividend (4.66%). Which is the better fit depends on your goals.
| BBY | REGN | |
|---|---|---|
Market Cap | $17.37B | $83.19B |
Sector | Consumer Cyclical | Health |
52-Week High | $90.17 | $812.27 |
52-Week Low | $55.52 | $555.51 |
Enterprise Value | $19.75B | $77.90B |
Dividend Yield | 4.66% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Best Buy (BBY) trades at $82.00, up 2.47% today, with a bearish technical signal and mixed sentiment. Recent earnings beats and a forward P/E of 15.19 suggest reasonable valuation, but revenue has declined from $51.8B in 2022 to $41.5B in 2025. The company is testing smaller store formats and appointed a new CFO in August 2026, aiming to stabilize operations amid leadership changes.
Outlook is cautious; analyst consensus is a Hold with a $81.69 price target. Opportunities include cost control and dividend yield, but risks involve persistent revenue pressure, competitive threats, and execution risks from management turnover. Net cash flow turned positive in 2025, yet margin compression remains a concern for sustained growth.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Best Buy Co Inc
With $51.8 billion in fiscal 2022 sales, Best Buy is the largest pure-play consumer electronics retailer in the U.S., with roughly 10.6% share of the aggregate market and north of 40% share of offline sales, per our calculations, CTA industry, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the COVID-19 pandemic, have seen the U.S. e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.
Read more on BBY →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
